Rocket Pharmaceuticals
(NASDAQ) RCKT
Rocket Pharmaceuticals Financials at a Glance
Market Cap
$409.31M
Revenue (TTM)
$0.00
Net Income (TTM)
$223.12M
EPS (TTM)
$-2.01
P/E Ratio
-1.88
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Price
$3.75
Volume
756,041
Open
$4.73
Price
$3.75
Volume
756,041
Open
$4.73
Previous Close
$3.75
Daily Range
$3.65 - $4.75
52-Week Range
$2.19 - $8.26
Dividend
$0.00
Beta (Volatility)
1.57 (High)
Price
$3.75
Volume
756,041
Open
$4.73
Previous Close
$3.75
Daily Range
$3.65 - $4.75
52-Week Range
$2.19 - $8.26
RCKT News
Biotech’s Year-End To-Do List
RCKT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Rocket Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
202
CEO
Gaurav D. Shah, MD
Website
www.rocketpharma.comHeadquarters
Cranbury, NJ 08512, US
RCKT Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-60%
Return on Capital
-77%
Return on Assets
-68%
Earnings Yield
-53.19%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$409.31M
Shares Outstanding
108.57M
Volume
756.04K
Short Interest
0.00%
Avg. Volume
3.15M
Financials (TTM)
Gross Profit
$11.03M
Operating Income
$228.52M
EBITDA
$210.21M
Operating Cash Flow
$190.01M
Capital Expenditure
$440.00K
Free Cash Flow
$190.45M
Cash & ST Invst.
$188.93M
Total Debt
$24.88M
Rocket Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$409.31M
N/A
Market Cap/Employee
$1.37M
N/A
Employees
299
N/A
Net Income
$42.54M
+29.5%
EBITDA
$37.01M
+35.6%
Quarterly Fundamentals
Net Cash
$164.05M
-52.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$21.96M
-3.0%
Short Term Debt
$2.92M
+2.0%
Return on Assets
-67.52%
N/A
Return on Invested Capital
-77.19%
N/A
Free Cash Flow
$34.92M
+26.1%
Operating Cash Flow
$34.84M
+25.8%